BioSpace News Archive

Preclinical data on XMT-1592, a NaPi2b-targeted site-specific and homogeneous Dolasynthen ADC, demonstrate excellent activity, tolerability and pharmacokinetics Preclinical data on multiple Immunosynthen STING-agonist ADCs show complete tumor regressions after a single dose, excellent tolerability and immune memory CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developi

- Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells - - Translational data expand on scientific rationale for both ongoing EMERGE Phase 2 trial and upcoming SELECT trial -

The Evolut TAVI Platform Receives New Indication for Patients with Bicuspid Aortic Valves at Extreme, High or Intermediate Risk of Surgical Mortality

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced preclinical data presentation for TG-1701, the Company’s highly selective, BTK inhibitor, at the 2020 American Association for Cancer Research (AACR) annual meeting, being held virtually. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are encouraged by the preclinical data presented today which showed TG-1701 to be just as active and more selective for

BERG, a clinical-stage biotech that employs artificial intelligence (AI) to research diseases and develop innovative treatments, today announced five presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting, being held from June 22- 24, 2020 .

PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II.

Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today plans to utilize its clinical-stage cancer immunotherapy StemVacs™ for treatment of COVID-19 patients. Previously

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematologic and oncologic diseases, today presented findings

TXR-311 was identified, screened and selected as an in vivo candidate and demonstrated efficacy comparable to sorafenib with good tolerability

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today presented a poster during the 2020 American Association for Cancer Research (AACR) annual meeting to be held